
A new report from Americans for Tax Fairness concludes:
“In addition to dodging its fair share of taxes, Pfizer—maker of Celebrex, Lipitor, Lyrica, and Viagra, among many other health-care products—has also been aggressively raising prescription drug prices, thereby straining patients and our health care system and in some cases putting needed medications out of reach.
By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once. In the company’s biggest insult to America yet, Pfizer’s merger will allow it to go on enjoying all the benefits of being based here—everything from a publicly educated workforce to an excellent communications infrastructure to a reliable patent system—without adequately paying to support them.”
The two wealth-extracting techniques go together, very often. This is what modern capitalism is increasingly becoming.
Why doesn’t Pfizer’s leadership focus on what it was originally set up to do: wealth creation? And don’t get us started on shareholder value.
Related articles

UN tax convention hub – updates & resources

A heartfelt farewell to our dear Óscar

Public finance is feminist terrain

New Tax Justice Network reports on real estate transparency
Beneficial Ownership of Real Estate Around the World
7 July 2026
Integrating the Collection, Use and Exchange of Real Estate Ownership Information
7 July 2026

Four definitions to change the world: Struggles over meaning in the UN tax convention negotiations

Fiscal hell or mirage? What Spain’s wage debate gets wrong

Introducing the Real Estate Secrecy Index

Indicator deep dive: Golden Visas

